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ARSTRACT 
Objectives: To determine the pattern of penicillin use in the 
treatment of pneumococcal pneumonia, and factors con- 
tributing to the use of alternative antibiotics. 
Methods: This study included all adult inpatients of St. Vin- 
cent’s Hospital and Medical Center who had documented 
pneumococcal pneumonia between December 1998 and Octo- 
ber 1999. St. Vincent’s is a 600 bed tertiary teaching hospital 
in New York City. Patients who had Streptococcus pneumo- 
niae isolated from a respiratory tract specimen were identified 
through microbiology laboratory records. A retrospective chart 
review of these patients was conducted, and those identified 
with clinical pneumonia were included in this study. Antibiotic 
use, patient demographics, resistance data, and clinician 
awareness of the antibiotic susceptibility results were noted. 
Results: Sixty adult patients hospitalized with documented 
pneumococcal pneumonia were identified. Thirteen (21.6%) of 
the 60 patients received penicillin or ampicillin. Susceptibility 
results were not noted in the medical record in 21 (35.0%) of 
the 60 patients, and none received penicillin. High rates of 
reported penicillin allergy in 8 (13.3%) of the 60 patients, and 
reluctance to use penicillin when isolates demonstrated inter- 
mediate susceptibility in 8 (13.3%) of the 60 patients were 
observed. 
Conclusions: Several remediable obstacles to penicillin use 
were identified in this study. An increased awareness of sus- 
ceptibility results by physicians and education of practitioners 
could have increased the use of penicillin as therapy to two- 
thirds of these patients. 
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The choice of empirical antibiotic therapy for community- 
acquired pneumonia has generated guidelines from sev- 
eral sources.L-3 If the etiology of the pneumonia can be 
established to be Streptococcus pneumoniae, penicillin 
therapy can be safely administered to non-allergic patients 
with susceptible or intermediately susceptible isolates. 
Fiscal concerns and the problem of increasing antibiotic 
resistance make identification of remediable obstacles to 
the use of narrower spectrum, less expensive antibiotics 
appropriate. The authors sought to determine the fre- 
quency of use of penicillin for documented pneumo- 
coccal pneumonia and to identify factors that resulted 
in the use of alternative agents. 
MATERIALS AND METHODS 
This study was conducted at St. Vincent’s Hospital and 
Medical Center, a 600 bed teaching hospital in New York 
City. All adult inpatients (>18 y of age) with a pneumo- 
coccus isolated from sputum or blood culture were iden- 
tified by the microbiology laboratory. From December 
1998 to October 1999, patients meeting these criteria 
were identified and chart reviews were performed. Only 
patients with a diagnosis of pneumonia were included in 
this study. Pneumonia was defined as a pulmonary it-Al- 
trate on chest radiograph and at least two of the follow- 
ing signs or symptoms: temperature over 38°C cough, 
pleuritic chest pain, dyspnea, and abnormal pulmonary 
examination by auscultation. Patient demographics, resis- 
tance data, antibiotic use, and duration of therapy were 
noted. Physician acknowledgment in the medical record 
of the culture growing Spneumoniae and its antibiotic 
susceptibility profile was also recorded. Symptoms and 
signs of pneumonia that developed 72 hours or longer 
after admission were considered nosocomial. 
Laboratory Methods 
Routine specimens sent for culture were processed using 
standard laboratory techniques. Blood cultures were 
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Table 1. Source and Susceptibility Profiles of Streptococcus pneumoniae from the 60 Study Patients 
Source 
Susceptibility Results Number of Isolates n = 60 Blood n = 29 (48%) Sputum n = 28 (47%) Both n = 3 15%J 
Susceptible 46 23 (50) 21 (46) 2 
Intermediate 
(4) 
a 4 (50) 3 (36) 1 
Resistant 
(13) 
6 2 (33) 4 (67) 0 
performed using the ESP Culture System II (Trek Diag- 
nostics, Westlake, OH). Bacterial isolates resembling pneu- 
mococci were tested for optochin susceptibility and bile 
solubility. 
Pneumococcal isolates obtained from respiratory sites 
were screened for susceptibility to penicillin using a l-ug 
oxacillin disk. Any isolate resistant to oxacillin was tested 
against penicillin, ceftriaxone, erythromycin, vancomycin, 
and a late generation quinolone by the E-test method (AB 
Biodisk, Piscataway, NJ) on Mueller-Hinton agar containing 
5% sheep blood. The Etest method was used to test pneu- 
mococcal isolates obtained from blood cultures. 
RESULTS 
Patient Demographics 
Sixty patients with pneumonia with or without bac- 
teremia attributable to S pneumoniae were evaluated. 
No patient had clinical or laboratory evidence of menin- 
gitis. Patient ages ranged from 21 to 97 years, the male- 
to-female ratio was 37:23, and there was a 13.3% all-cause 
mortality. Of the eight patients who died, six had a peni- 
cillin-susceptible isolate and one patient each had an 
intermediate and a high-level resistant isolate. Fifty-five 
patients had community-acquired pneumonia and five 
cases were nosocomial. The most common predisposing 
condition was human immunodeficiency virus (HIV) 
infection (22/6O; 36.7% of patients). 
Pneumococcal Isolates 
The source and susceptibility of the S.pneumoniae iso- 
lates from the 60 patients are shown in Table 1. 
Antibiotic Use 
No patient received empirical penicillin (or ampicillin). 
Overall, 13 (21%) of 60 patients received penicillin or 
ampicillin sometime during their hospital stay. Suscepti- 
bility results were not acknowledged in the medical 
records in 21 (35%) of 60 patients. Where results were 
noted, only 16 (41%) were acknowledged within 3 days 
of obtaining the specimen (mean, 3.97 d). Physician 
awareness of culture susceptibility results prompted a 
change to penicillin in 13 of 39 patients or to other nar- 
rower spectrum agents (3 cefazolin, 1 cephalexin, 2 
cefuroxime) in an additional six patients. This therapeu- 
tic change occurred a mean of 5.9 days after the sample 
was obtained for culture and 2 days, on average, after sus- 
ceptibility results were acknowledged on the chart. No 
patient with an intermediately susceptible isolate received 
penicillin or ampicillin. There were no changes in ther- 
apy if the physician did not acknowledge the suscepti- 
bility results in the medical record. 
The most often prescribed antibiotic was ceftriax- 
one with or without a macrolide. Five patients initially 
received a quinolone as empirical therapy and nine 
patients were discharged on oral quinolone therapy. Only 
five patients were prescribed oral penicillin at discharge 
from the hospital. 
A history of penicillin allergy was noted in 8 (13.3%) 
of 60 patients, one with a documented history of ana- 
phylaxis. Among 10% of patients (G/60) death or dis- 
charge occurred before susceptibility data were available. 
Six patients had high-level resistant isolates. Suspected 
or documented concurrent infection with one or more 
additional organisms was seen in nine patients (15%). 
Five patients had more than one contraindication for 
penicillin use. 
There were 23 additional patients who could have 
received penicillin therapy based on the length of their 
hospital stay, susceptible isolates, lack of penicillin allergy, 
and who were without a concurrent infection. There- 
fore, penicillin could have been used to treat a minimum 
of 36 patients or 60% of those individuals included in this 
study. 
DISCUSSION 
In this study population, the use of penicillin (or ampi- 
cillin) for the treatment of documented pneumococcal 
pneumonia was low, with only 13 (2 1.6%) of 60 patients 
receiving this therapy. When changes in therapy were 
instituted, they came late in the hospital stay for those still 
hospitalized. 
The most common remediable obstacle to the use 
of penicillin was lack of physician awareness of suscep- 
tibility results. Where the susceptibility results were not 
known, no changes in therapy were made. Secondly, 
patients with intermediately susceptible isolates were 
never prescribed penicillin despite evidence that peni- 
cillin can be safely and effectively used for this clinical 
indication.3-5 Lastly, the rate of penicillin allergy was 
higher than the prevalence of a history of penicillin 
allergy in the American population, which is estimated to 
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be between 5% and lo%.“,’ No details of the allergic his- 
tory were documented in seven of eight patients with a 
reported history of allergy. 
Non-remediable obstacles to penicillin use included 
isolates with high-level resistance, true penicillin allergy, 
early discharge from hospital (within 3 d of admission) 
or death, and suspected or documented concurrent infec- 
tions. Therefore, in approximately one-third of the 
patients, some patients having multiple exclusion factors, 
alternative therapy was appropriate. The results of this ret- 
rospective study performed at a single institution may 
not reflect patterns of penicillin use in other institutions. 
Studies suggest that Spneumoniae causes between 
9% and 55% of cases of community-acquired pneumo- 
nia requiring admittance to hospital and 500,000 cases 
of pneumonia in the American population.8-1” There- 
fore, interventions to facilitate the use of penicillin for 
these infections could have both a fiscal and a medical 
impact. Improved communication between the labora- 
tory and clinical staff when susceptibility results become 
available and education concerning the efficacy of peni- 
cillin for intermediately susceptible isolates could have 
the largest effect on prescribing practices. The suggested 
changes in the National Committee for Clinical Labora- 
tory Standards (NCCLS) breakpoints for S.pneumoniae 
to penicillin for infections other than meningitis may 
also alleviate this prob1em.j Finally, prompt skin testing 
to detect true allergy to penicillin would allow use of 
this agent during hospitalization and after discharge, in 
non-allergic patients. Negative skin tests carry a 1% to 
4% risk of cutaneous reaction to penicillin used as ther- 
apy and no life-threatening reactions have been 
reported.‘*-I6 
These interventions could have a significant impact 
on prescribing practices and reserve the use of broad- 
spectrum, more expensive agents for the appropriate 
patient. 
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